{"id":461062,"date":"2021-03-18T16:08:10","date_gmt":"2021-03-18T20:08:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=461062"},"modified":"2021-03-18T16:08:10","modified_gmt":"2021-03-18T20:08:10","slug":"trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/","title":{"rendered":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25"},"content":{"rendered":"<h2>\nConference Call and Webcast to be Held at 4:30 p.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">NEW HAVEN, Conn., March  18, 2021  (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio\u2122 (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Company\u2019s financial results for the quarter and year ended December 31, 2020.<\/p>\n<p>To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 8599904. A live audio webcast will be accessible from the \u2018Investors &amp; News\u2019 section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qmEWj_yk5M0GakqYCkCNNOOQ_yfk6QS9-t3SoqSzb-mROsNUV2nLeuYZvU_F5imRuyfzc6TYPMdKsrN5ZoaMHxut6quihD5BPWgOklSVLJ4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.trevitherapeutics.com<\/a>. An archived replay of the webcast will also be available for 30 days on the Company\u2019s website following the event.<\/p>\n<p>\n        <strong>About\u00a0Trevi Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Trevi Therapeutics, Inc.\u00a0is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.\u00a0Trevi\u00a0is conducting a Phase 2b\/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson\u2019s disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.<\/p>\n<p>Founded in 2011,\u00a0Trevi Therapeutics\u00a0is headquartered in\u00a0New Haven, CT.<\/p>\n<p>\n        <strong>About HADUVIO<\/strong><br \/>\n        <br \/>Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed \u0138-opioid receptor agonist and \u00b5-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in\u00a0the United States\u00a0and\u00a0Europe. The \u0138- and \u00b5-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine\u2019s mechanism of action also mitigates the risk of abuse associated with \u00b5-opioid agonists because it antagonizes, or blocks, \u00b5-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in\u00a0the United States\u00a0and most of\u00a0Europe.\u00a0Trevi\u00a0intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Eric Ribner<br \/>LifeSci Advisors<br \/>917 592 0932<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OVQ_YN_e3iQ-pDC8Yk72VGXZPdvFc0dk7HJfBjGppdEipJ5orP20JHgPOCRqMrbbBep0IMtGeYdIOZ6Gfp0i586O58ROJ10PhwoEczXWcCk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Eric@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\u00a0\u00a0 <br \/>Rosalia Scampoli<br \/>914-815-1465<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SeL3OPu8SpcBvUW6ipLvnDA-Te3sH7t42oM3VKXuqNXqofRwZr5WOddhoe5il4cZTIwFblY66s0kSVIXR0SuCxQn8UrXuVLbVHdIkQtaChY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rscampoli@marketcompr.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6556a21d-191c-4b0d-a3e2-a874601992b4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio\u2122 (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Company\u2019s financial results for the quarter and year ended December 31, 2020. To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 8599904. A live audio webcast will be accessible from the \u2018Investors &amp; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-461062","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio\u2122 (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Company\u2019s financial results for the quarter and year ended December 31, 2020. To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 8599904. A live audio webcast will be accessible from the \u2018Investors &amp; &hellip; Continue reading &quot;Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-18T20:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25\",\"datePublished\":\"2021-03-18T20:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/\"},\"wordCount\":436,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/\",\"name\":\"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\",\"datePublished\":\"2021-03-18T20:08:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk","og_description":"Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) &#8212; Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio\u2122 (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Company\u2019s financial results for the quarter and year ended December 31, 2020. To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 8599904. A live audio webcast will be accessible from the \u2018Investors &amp; &hellip; Continue reading \"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-18T20:08:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25","datePublished":"2021-03-18T20:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/"},"wordCount":436,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/","name":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=","datePublished":"2021-03-18T20:08:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5Mjc4MSM0MDcxNjQxIzIxMjUxMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-report-q4-and-year-end-2020-financial-results-on-march-25\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/461062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=461062"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/461062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=461062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=461062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=461062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}